DSCSA Compliance Updates for Independent Pharmacies in 2026

Independent pharmacies face new verification obligations under the Drug Supply Chain Security Act (DSCSA) effective November 27, 2026, when FDA enforcement begins for enhanced verification of product identifiers at the package level. This impacts wholesale drug distributors who supply independent pharmacies, as pharmacies will require transaction data in ATP-compliant formats to meet verification requirements.

Regulatory Context

The DSCSA, enacted under Title II of the Drug Quality and Security Act of 2013, establishes requirements for pharmaceutical supply chain traceability through serialization and verification systems. Phase-in compliance dates for different trading partner classes have been staggered since 2015. Wholesale drug distributors have been required to maintain ATP-compliant systems for product tracing since November 2023 under 21 USC 360eee-1(b). The November 2026 deadline extends enhanced verification requirements to dispensers — primarily retail and independent pharmacies.

Under 21 USC 360eee-3(d)(1)(A), dispensers must verify product identifiers for suspect or illegitimate products. Beginning November 27, 2026, FDA guidance indicates this verification must occur at the package level using serialized data elements: National Drug Code (NDC), serial number, lot number, and expiration date. Pharmacies cannot meet this requirement using manual lot-level verification processes that were acceptable under interim enforcement discretion.

Key Verification Requirements

Independent pharmacies must establish systems to:

1. Receive and store serialized transaction data from upstream trading partners (wholesalers and distributors) in EPCIS 1.2 or higher format
2. Query verification routers or manufacturer VRS endpoints to confirm product authenticity when suspect products are identified
3. Quarantine and investigate products that fail verification before dispensing
4. Maintain electronic records of transaction information, transaction history, and transaction statements for six years per 21 USC 360eee-1(b)(1)(A)(i)

FDA has not mandated specific technology implementations, but industry adoption centers on three approaches: direct EPCIS integration with wholesaler systems, third-party verification service platforms, and cloud-based ATP solutions offered by pharmacy system vendors. All three models require wholesalers to provide serialized data in structured electronic formats.

Impact on Wholesale Distributors

Wholesale drug distributors serving independent pharmacies must confirm their ATP systems can export serialized transaction data in formats independent pharmacies can ingest. This affects three operational areas:

Data transmission infrastructure: Distributors using proprietary ATP systems must establish EPCIS export functionality or API connections to pharmacy-side verification platforms. Order confirmation and shipping documentation workflows must include serialized data elements, not just lot-level information.

Customer onboarding: Independent pharmacies purchasing from multiple wholesalers may lack IT resources to integrate with each distributor's unique data format. Distributors face increased technical support requests for data format compatibility, EPCIS schema questions, and transaction data troubleshooting. Some distributors are absorbing these costs; others are directing pharmacies to third-party aggregation services.

Compliance verification documentation: Under 21 USC 360eee-1(d)(1)(C), distributors must only conduct transactions with authorized trading partners. Pharmacies unable to receive ATP-compliant data after November 27, 2026 create compliance risk for their upstream wholesalers. Distributors conducting due diligence on pharmacy customers now include questions about verification system readiness in trading partner qualification workflows.

The FDA has not issued draft guidance on enforcement discretion timelines. Independent pharmacy trade associations have requested a delayed enforcement date, citing implementation costs for smaller dispensers. As of January 2025, FDA has not indicated any extension beyond the statutory November 27, 2026 deadline.

Distributors serving independent pharmacy customers should confirm their transaction data export capabilities meet EPCIS requirements and establish technical support protocols for pharmacy-side integration issues before Q4 2026.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, 1,234 hold active FDA registration — a baseline requirement for ATP compliance under DSCSA. However, the average compliance score of 51/100 across all entities indicates that many distributors have limited verified compliance signals beyond basic federal registration. Only 63 entities hold NABP accreditation (formerly VAWD), which requires documented ATP system capabilities as part of the accreditation standards.

The score distribution reveals potential readiness gaps: 919 entities (72%) fall in the "Fair" tier (41-60 points), meaning they have FDA registration and some state licenses verified, but lack NABP accreditation or have incomplete compliance documentation in publicly available sources. For independent pharmacies evaluating whether their current wholesaler can provide EPCIS-formatted serialized data, a distributor's compliance score offers one signal of operational maturity — entities with NABP accreditation have undergone third-party verification of their traceability systems.

The 73 entities with FDA recalls on record warrant additional scrutiny. While most recalls reflect product-level issues unrelated to ATP compliance, pharmacies conducting trading partner due diligence should verify whether their wholesaler has documented corrective actions for any recall related to transaction data accuracy or traceability failures.

Practical Guidance for Compliance Teams

For independent pharmacy procurement/QA teams:

• Review your current wholesaler's compliance profile in the ColdChainCheck directory. Confirm FDA registration is active and check for NABP accreditation status. Entities with accreditation have documented ATP capabilities verified by a third party.
• Contact wholesalers lacking NABP accreditation to request documentation of their EPCIS export capabilities. Ask for sample transaction data files in structured format before November 2026.
• If your primary distributor scores below 50 points, conduct enhanced due diligence. Lower scores may indicate limited public compliance documentation — not necessarily non-compliance, but less transparency.

For wholesale distributors:

• Audit your customer base for independent pharmacy accounts. Entities without in-house IT staff may require simplified data export formats or referrals to third-party aggregation services.
• Document your ATP system's EPCIS compatibility in customer-facing materials. QA teams evaluating trading partners will request this documentation as part of their November 2026 readiness audits.

ColdChainCheck tracks FDA registration status, NABP accreditation, and recall history as compliance signals. For broader DSCSA compliance guidance, see the regulatory guides section.

Disclaimer: This article is provided for informational purposes only and does not constitute legal or regulatory advice. Compliance requirements should be verified with legal counsel and the relevant regulatory authorities.

Update: DSCSA 2026 Requirements | Nov + Sep Deadlines — ColdChainCheck

April 16, 2026

DSCSA 2026 Developments: Independent Pharmacy Exemption Deadline and 12-Digit NDC Transition

The Drug Supply Chain Security Act faces two critical compliance milestones in 2026: independent pharmacies lose their exemption from electronic interoperable tracing requirements on November 27, 2026, and the pharmaceutical industry must complete its transition to 12-digit National Drug Code formats by September 30, 2026. Both deadlines carry direct operational consequences for wholesale drug distributors managing transaction data and product master files.

Regulatory Context

The DSCSA (Public Law 113-54), enacted November 27, 2013, established a phased implementation timeline for building an electronic, interoperable system to identify and trace prescription drugs as they move through the U.S. supply chain. The law requires pharmaceutical manufacturers, repackagers, wholesale distributors, and dispensers to exchange transaction information (TI), transaction history (TH), and transaction statements (TS) in standardized electronic formats.

The independent pharmacy exemption, codified in the DSCSA's dispenser requirements under Section 582(d)(4), temporarily allowed pharmacies with annual prescription volumes below specific thresholds to defer full electronic tracing compliance. This exemption expires November 27, 2026—exactly 13 years after the DSCSA's enactment—requiring all dispensers to comply with the same interoperable exchange standards as other trading partners.

The 12-digit NDC requirement stems from FDA's final guidance issued June 2024, mandating that all product identifiers in EPCIS transaction data use the standard 5-4-2 NDC configuration (5-digit labeler code, 4-digit product code, 2-digit package code). The September 30, 2026 deadline applies to all DSCSA-covered entities, including wholesale drug distributors transmitting transaction information to trading partners.

Independent Pharmacy Exemption Expiration

Under current regulations, independent pharmacies meeting size criteria have operated under modified DSCSA requirements: accepting paper transaction documentation, maintaining paper records, and conducting product verification using manual processes. After November 27, 2026, these pharmacies must:

• Accept transaction information in electronic format only (no paper TI/TH/TS)
• Maintain EPCIS-compatible systems for receiving and storing transaction data
• Conduct product verification through electronic interoperable systems
• Respond to verification requests within 24 hours using electronic protocols

Wholesale drug distributors shipping to independent pharmacies will no longer be permitted to provide paper documentation. All transaction information must be transmitted via ATP (Authorized Trading Partner) verified systems using EPCIS 1.2 or later standards. This eliminates the hybrid paper-electronic workflows many distributors maintain for smaller pharmacy customers.

For 3PLs managing distribution on behalf of manufacturer clients, the exemption expiration requires system validation that all dispenser recipients can receive electronic TI. Current drop-ship processes that accommodate paper documentation for independent pharmacies must be phased out by the November deadline.

12-Digit NDC Format Mandate

FDA's 12-digit NDC requirement addresses a long-standing data standardization issue: NDC formats vary in their digit configuration (10-digit with varying segment lengths: 4-4-2, 5-3-2, 5-4-1). EPCIS transaction data has historically contained inconsistent NDC formats, creating matching failures between trading partners' systems.

Starting September 30, 2026, all EPCIS transaction data exchanged under DSCSA must use the standardized 12-digit format: 5-digit labeler code, 4-digit product code, 2-digit package code. Leading zeros must be added to shorter segment configurations to reach the standard format.

Example conversions:

• 4-4-2 format (0378-6205-77) becomes 5-4-2 format (00378-6205-77)
• 5-3-2 format (12345-678-90) becomes 5-4-2 format (12345-0678-90)
• 5-4-1 format (54868-1234-5) becomes 5-4-2 format (54868-1234-05)

Wholesale distributors must update product master files, transaction information templates, and EPCIS message schemas to align with the 12-digit standard. Legacy systems relying on 10-digit NDC fields will require database schema modifications and validation logic updates.

Distributor Impact Assessment

Both 2026 milestones create concrete operational requirements for wholesale drug distributors:

System readiness for universal electronic exchange: Distributors with independent pharmacy customers must confirm those customers' ATP status and EPCIS capability before November 27, 2026. Trading partner onboarding processes must verify electronic system compatibility—paper acceptance is no longer a fallback option. Customer segmentation strategies based on paper-vs-electronic workflows become obsolete.

NDC data remediation timelines: The September 30, 2026 NDC deadline requires distributors to audit and remediate existing product master files. For entities managing 10,000+ SKUs, this involves systematic conversion of legacy NDC formats, validation against FDA's National Drug Code Directory, and coordination with ERP/WMS vendors to ensure field-level compatibility. Transaction information transmitted after September 30, 2026 in non-compliant NDC formats will fail interoperability checks, triggering verification request workflows.

Verification request volume: As independent pharmacies transition to electronic systems, wholesale distributors should anticipate increased product verification requests during the Q4 2026 transition window. Pharmacy systems newly online will likely generate higher false-positive alerts as staff adapt to electronic verification protocols.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors tracked in ColdChainCheck's directory, 1,234 hold active FDA registration—a baseline DSCSA requirement. However, the average compliance score of 51/100 suggests significant variability in verified compliance signals across the industry. Only 63 entities hold NABP accreditation (formerly VAWD), which requires demonstrated compliance with DSCSA electronic transaction requirements as part of the accreditation criteria.

The score distribution reveals that 919 entities (72% of tracked distributors) fall in the "Fair" tier (40-59 points), indicating partial verification of compliance signals but gaps in publicly available data confirming full DSCSA readiness. Just 28 entities (2%) score in the "Excellent" tier (80-100 points), reflecting comprehensive verification across state licensure, federal registration, accreditation, and clean enforcement records.

This distribution matters for the 2026 milestones: distributors in the Fair tier may hold required FDA registration but lack third-party verification of their EPCIS capabilities or NDC data quality. Entities with NABP accreditation have undergone on-site audits confirming ATP status and electronic transaction infrastructure—a stronger signal for trading partners evaluating 2026 readiness.

Practical steps for compliance teams:

• Audit your current distributor roster — Use the ColdChainCheck directory to identify which trading partners hold NABP accreditation. Accredited entities have already demonstrated EPCIS compliance to NABP auditors. Non-accredited entities require direct validation of their ATP status and system capabilities before November 27, 2026.

• Request NDC format confirmation — Contact wholesale distributors to verify their timeline for 12-digit NDC transition. Entities scoring below 60 in ColdChainCheck may have outdated product master file management practices. Request sample EPCIS transaction data to validate NDC format compliance ahead of the September deadline.

• Monitor for enforcement signals — ColdChainCheck tracks FDA warning letters and recalls. Of the 1,275 tracked entities, 73 have recalls on record. Review the enforcement history of critical trading partners—entities with recent DSCSA-related citations may face delays meeting 2026 requirements.

• Document due diligence — Maintain records of trading partner verification activities. If a distributor fails to meet November 2026 electronic exchange requirements, documented attempts to verify their compliance support your own regulatory defense during audits.

ColdChainCheck will continue tracking DSCSA-related compliance signals as entities approach the 2026 deadlines. For broader context on wholesale distributor qualification requirements, see the DSCSA compliance checklist.

Disclaimer: This article provides informational analysis of DSCSA regulatory developments based on publicly available sources. It is not legal or compliance advice. Readers should consult qualified legal counsel and verify current requirements with FDA and relevant state authorities before making operational decisions.